FDA Grants Birelentinib Fast Track Designation for Patients With Relapsed or Refractory CLL/SLL - Prabadin Corp

Email

weborders@prabadincorp.com

Call us

+1 (786)-332-3938

$FDA Grants Birelentinib Fast Track Designation for Patients With Relapsed or Refractory CLL/SLL$

Health

August 7, 2025

By AdminPrabadin - 1 day ago

0

Birelentinib gains FDA fast track designation, offering hope for relapsed CLL/SLL patients resistant to current BTK and BCL-2 therapies.

administrator